Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Oxford BioDynamics' new blood test for Chronic Fatigue Syndrome shows 96% accuracy, sparking a 33% stock surge.

flag Oxford BioDynamics PLC announced a highly accurate blood test for Chronic Fatigue Syndrome with 96% accuracy, developed with the University of East Anglia, triggering a 33% share surge. flag The test, a first-in-class diagnostic tool, aims to provide faster, reliable diagnoses for a condition long hindered by unclear biomarkers. flag Meanwhile, Conroy Gold and Natural Resources raised £1.73 million in an oversubscribed share placement, boosting its stock. flag Pantheon Resources completed a successful hydraulic fracturing operation at its Alaska well with no incidents, advancing its project. flag ANGLE PLC rebranded to CelLBxHealth and shifted strategy under new leadership to strengthen its oncology diagnostics focus.

8 Articles